[go: up one dir, main page]

CO6531464A2 - Morfolinotiazoles como moduladores alostéricos positivos alfa 7 - Google Patents

Morfolinotiazoles como moduladores alostéricos positivos alfa 7

Info

Publication number
CO6531464A2
CO6531464A2 CO12065796A CO12065796A CO6531464A2 CO 6531464 A2 CO6531464 A2 CO 6531464A2 CO 12065796 A CO12065796 A CO 12065796A CO 12065796 A CO12065796 A CO 12065796A CO 6531464 A2 CO6531464 A2 CO 6531464A2
Authority
CO
Colombia
Prior art keywords
morpholinotiazols
alfa
preparing
compositions containing
pharmaceutical compositions
Prior art date
Application number
CO12065796A
Other languages
English (en)
Inventor
Gregor James Macdonald
Joseph Elisabeth Leenaerts
Boeck Benoit Christian De
Boeck Albert Ghislain De
Original Assignee
Jassenb Farmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jassenb Farmaceutica Nv filed Critical Jassenb Farmaceutica Nv
Publication of CO6531464A2 publication Critical patent/CO6531464A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a derivados morfolinotiazol y sus sales farmacéuticamente aceptables, procesos para prepararlos, composiciones farmacéuticas que los contienen y sus usos en terapia. La invención en particular se refiere a moduladores alostéricos positivos de receptores acetilcolina nicotínicos, dichos moduladores alostéricos positivos que tengan la capacidad de aumentar la eficacia de agonistas del receptor nicotínico.Sector: Industria farmacéutica, específicamente nuevos derivados morfolinotiazol y composiciones farmacéuticas que los contienen, útiles para el tratamiento de enfermedades del sistema nervioso. Asimismo, la presente invención revela procesos de preparación de tales derivados morfolinotiazol.
CO12065796A 2009-11-27 2012-04-20 Morfolinotiazoles como moduladores alostéricos positivos alfa 7 CO6531464A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09177347 2009-11-27

Publications (1)

Publication Number Publication Date
CO6531464A2 true CO6531464A2 (es) 2012-09-28

Family

ID=42010343

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12065796A CO6531464A2 (es) 2009-11-27 2012-04-20 Morfolinotiazoles como moduladores alostéricos positivos alfa 7

Country Status (25)

Country Link
US (1) US8637510B2 (es)
EP (1) EP2504333B1 (es)
JP (1) JP5636434B2 (es)
KR (1) KR101749953B1 (es)
CN (1) CN102639530B (es)
AR (1) AR079205A1 (es)
AU (1) AU2010323175B2 (es)
BR (1) BR112012012657A2 (es)
CA (1) CA2780218C (es)
CL (1) CL2012001366A1 (es)
CO (1) CO6531464A2 (es)
DK (1) DK2504333T3 (es)
EA (1) EA020275B1 (es)
ES (1) ES2549917T3 (es)
IL (1) IL219926A0 (es)
JO (1) JO3078B1 (es)
MX (1) MX349585B (es)
MY (1) MY160728A (es)
NZ (1) NZ600138A (es)
PL (1) PL2504333T3 (es)
SG (1) SG181054A1 (es)
TW (1) TWI473803B (es)
UA (1) UA106636C2 (es)
WO (1) WO2011064288A1 (es)
ZA (1) ZA201203856B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
CA2697974C (en) * 2007-10-18 2015-06-30 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
CL2009000662A1 (es) * 2008-03-19 2010-02-05 Janssen Pharmaceutica Nv Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
CL2009001125A1 (es) * 2008-05-09 2011-02-11 Janssen Pharmaceutica Nv Compuestos derivados de pirazol trisustituido, moduladores alostericos positivos de los receptores ach nicotinicos; composicion farmaceutica que los comprende; proceso de preparacion de la composicion; y su uso en el tratamiento de enfermedades de snc o inflamatorias.
PT3029039T (pt) 2010-05-17 2017-11-28 Forum Pharmaceuticals Inc Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
US20130310419A1 (en) 2011-02-03 2013-11-21 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
AU2012221800B2 (en) 2011-02-23 2016-10-27 Lupin Limited Heteroaryl derivatives as alpha7 nAChR modulators
KR20140025395A (ko) 2011-03-31 2014-03-04 루핀 리미티드 알츠하이머병 및 파킨슨병을 포함하는 신경병성 장애 치료용 니코틴성 아세틸콜린 수용체 조절인자로서의 피롤 유도체
EP2729455B1 (en) 2011-07-05 2016-09-14 Lupin Limited Biaryl derivatives as nachr modulators
EP2822946A1 (en) * 2012-03-06 2015-01-14 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
EP2846796A4 (en) 2012-05-08 2015-10-21 Forum Pharmaceuticals Inc METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION
EP2945936A1 (en) 2012-11-12 2015-11-25 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
US9617211B2 (en) 2013-01-16 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
CA2892682A1 (en) 2013-03-13 2014-09-18 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
CA2913987A1 (en) 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
AU2017313390A1 (en) * 2016-08-19 2019-03-07 The University Of Bristol Cytisine derivatives for the treatment of addiction
US20220040158A1 (en) * 2018-09-24 2022-02-10 Astrazeneca Ab Azd0328 dosage regime for treating cognitive impairment
CA3155379A1 (en) * 2019-10-21 2021-04-29 Kiri GRANGER Schizophrenic disorder treatment using combination therapy
CN115317480B (zh) * 2022-09-01 2023-05-16 新乡医学院 N-(3-甲基-5-异噻唑基)-2-氧代-3-(2h)-苯并噁唑乙酰胺的药物应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004506735A (ja) * 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
AU2004229392A1 (en) 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
EP1884513A4 (en) 2005-05-23 2010-04-28 Japan Tobacco Inc PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME
ES2632940T3 (es) * 2005-09-13 2017-09-18 Janssen Pharmaceutica Nv Derivados de tiazol sustituidos con 2-anilin-4-arilo
CN101374810A (zh) * 2006-01-18 2009-02-25 锡耶纳生物技术股份公司 α7烟碱型乙酰胆碱受体的调节剂及其治疗用途
JO3019B1 (ar) * 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
EA017726B1 (ru) * 2008-04-17 2013-02-28 Глэксо Груп Лимитед Индолы в качестве модуляторов никотинового рецептора ацетилхолина подтипа альфа-7
SG10201801956SA (en) 2013-09-09 2018-04-27 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same

Also Published As

Publication number Publication date
UA106636C2 (uk) 2014-09-25
AU2010323175B2 (en) 2014-06-26
KR101749953B1 (ko) 2017-06-22
EP2504333B1 (en) 2015-07-15
PL2504333T3 (pl) 2015-12-31
TW201127836A (en) 2011-08-16
AR079205A1 (es) 2012-01-04
CA2780218C (en) 2018-10-16
BR112012012657A2 (pt) 2016-07-12
MY160728A (en) 2017-03-15
HK1171449A1 (en) 2013-03-28
JO3078B1 (ar) 2017-03-15
NZ600138A (en) 2013-05-31
MX2012006082A (es) 2012-06-19
JP5636434B2 (ja) 2014-12-03
CN102639530A (zh) 2012-08-15
ES2549917T3 (es) 2015-11-03
EA201290394A1 (ru) 2012-10-30
CN102639530B (zh) 2014-08-06
SG181054A1 (en) 2012-07-30
TWI473803B (zh) 2015-02-21
DK2504333T3 (en) 2015-10-19
EA020275B1 (ru) 2014-09-30
AU2010323175A1 (en) 2012-05-10
IL219926A0 (en) 2012-07-31
US20120238561A1 (en) 2012-09-20
CA2780218A1 (en) 2011-06-03
MX349585B (es) 2017-08-03
JP2013512218A (ja) 2013-04-11
US8637510B2 (en) 2014-01-28
KR20120102083A (ko) 2012-09-17
ZA201203856B (en) 2015-01-28
EP2504333A1 (en) 2012-10-03
CL2012001366A1 (es) 2012-10-05
WO2011064288A1 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
CO6531464A2 (es) Morfolinotiazoles como moduladores alostéricos positivos alfa 7
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
CU20130094A7 (es) Moduladores de la vía del complemento
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
UY33536A (es) INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
ECSP15022555A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
GT201400062A (es) Composiciones farmacéuticas que comprenden 40-o-(2-hidroxi) etil-rapamicina
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
NI201400102A (es) Derivados macrocíclicos para el tratamiento de enfermedades proliferativas
UY33483A (es) Acidos de hidroxifenilhexinoico ariloxialquileno-sustituido, procedimiento para su preparacion y su uso como medicamento.
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
ECSP14013217A (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk.
BR112014027359A2 (pt) moduladores da série de reação complementar e usos dos mesmos
CU24177B1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
CO6491096A2 (es) Derivados de cromona, procesos para su preparación y aplicaciones terapeúticas de los mismos
CR20130530A (es) Derivados glucósidos y sus usos para el tratamiento de la diabetes
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato

Legal Events

Date Code Title Description
FG Application granted